Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta (25-35)

Behavioural Brain Research

Volumn 190, Issue 2, 2008, Pages 224-232

  Tsunekawa, Hiroko ^b,c   Noda, Yukihiro ^b,d   Mouri, Akihiro ^a,b   Yoneda, Fumio ^c   Nabeshima, Toshitaka ^a,b,e  

^a MEIJO UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Research Institute   (Japan)

^d Faculty of Pharmacy   (Japan)

^e Japanese Drug Organization of Appropriate Use and Research   (Japan)

Author keywords

Alzheimer's disease (AD); Amyloid beta (25 35) A (25 35) ; Cholinergic systems; Cognitive impairment; Donepezil; Dopaminergic systems; Selegiline

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; CHOLINESTERASE INHIBITOR; DONEPEZIL; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; MONOAMINE OXIDASE B INHIBITOR; MUSCARINIC RECEPTOR BLOCKING AGENT; SCOPOLAMINE; SELEGILINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLINERGIC SYSTEM; COGNITION; COGNITIVE DEFECT; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG POTENTIATION; FEAR; LEARNING DISORDER; MALE; MAZE TEST; MEMORY DISORDER; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RECOGNITION; TASK PERFORMANCE; TREATMENT RESPONSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ASSOCIATION LEARNING; COGNITION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; INDANS; MALE; MAZE LEARNING; MICE; MICE, INBRED ICR; NEUROPROTECTIVE AGENTS; NOOTROPIC AGENTS; PEPTIDE FRAGMENTS; PIPERIDINES; RECOGNITION (PSYCHOLOGY); SELEGILINE; SINGLE-BLIND METHOD; STATISTICS, NONPARAMETRIC;

EID: 42249083032     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2008.03.002     Document Type: Article

References (43)

1. Abramov A.Y., Canevari L., and Duchen M.R. Changes in intracellular calcium and glutathione in astrocytes as the primary mechanism of amyloid neurotoxicity. J Neurosci 23 12 (2003) 5088-5095
2. Birkmayer W., Knoll J., Riederer P., Youdim M.B., Hars V., and Marton J. Increased life expectancy resulting from addition of l-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J Neural Transm 64 2 (1985) 113-127
3. Brandeis R., Sapir M., Kapon Y., Borelli G., Cadel S., and Valsecchi B. Improvement of cognitive function by MAO-B inhibitor l-deprenyl in aged rats. Pharmacol Biochem Behav 39 2 (1991) 297-304
4. Choi J., Malakowsky C.A., Talent J.M., Conrad C.C., Carroll C.A., Weintraub S.T., et al. Anti-apoptotic proteins are oxidized by Abeta 25-35 in Alzheimer's fibroblasts. Biochim Biophys Acta 1637 2 (2003) 135-141
5. Dong H., Csernansky C.A., Martin M.V., Bertchume A., Vallera D., and Csernansky J.G. Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer's disease. Psychopharmacology (Berlin) 181 1 (2005) 145-152
6. Dringenberg H.C., Laporte P.P., and Diavolitsis P. Increased effectiveness of tacrine by deprenyl co-treatment in rats: EEG and behavioral evidence. Neuroreport 11 16 (2000) 3513-3516
7. Enomoto T., Noda Y., Mouri A., Shin E.J., Wang D., Murai R., et al. Long-lasting impairment of associative learning is correlated with a dysfunction of N-methyl-d-aspartate-extracellular signaling-regulated kinase signaling in mice after withdrawal from repeated administration of phencyclidine. Mol Pharmacol 68 6 (2005) 1765-1774
8. Fujishiro H., Umegaki H., Suzuki Y., Oohara-Kurotani S., Yamaguchi Y., and Iguchi A. Dopamine D2 receptor plays a role in memory function: implications of dopamine-acetylcholine interaction in the ventral hippocampus. Psychopharmacology (Berlin) 182 2 (2005) 253-261
9. Gasbarri A., Sulli A., Innocenzi R., Pacitti C., and Brioni J.D. Spatial memory impairment induced by lesion of the mesohippocampal dopaminergic system in the rat. Neuroscience 74 4 (1996) 1037-1044
10. Gu M., Owen A.D., Toffa S.E., Cooper J.M., Dexter D.T., Jenner P., et al. Mitochondrial function. GSH and iron in neurodegeneration and Lewy body diseases. J Neurol Sci 158 1 (1998) 24-29
11. Hersi A.I., Kitaichi K., Srivastava L.K., Gaudreau P., and Quirion R. Dopamine D-5 receptor modulates hippocampal acetylcholine release. Brain Res Mol Brain Res 76 2 (2000) 336-340
12. Hiramatsu M., Watanabe M., Baba S., Kojima R., and Nabeshima T. Alpha 7-type nicotinic acetylcholine receptor and prodynorphin mRNA expression after administration of (-)-nicotine and U-50. 488H in beta-amyloid peptide (25-35)-treated mice. Ann N Y Acad Sci 1025 (2004) 508-514
13. Howell G.J. Use of tacrine hydrochloride (Cognex) in private practice. Acta Neurol Scand Suppl 165 (1996) 123-127
14. Jann M.W., Shirley K.L., and Small G.W. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 41 10 (2002) 719-739
15. Kamei H., Nagai T., Nakano H., Togan Y., Takayanagi M., Takahashi K., et al. Repeated methamphetamine treatment impairs recognition memory through a failure of novelty-induced ERK1/2 activation in the prefrontal cortex of mice. Biol Psychiatry 59 1 (2006) 75-84
16. Kato K., Hayako H., Ishihara Y., Marui S., Iwane M., and Miyamoto M. TAK-147, an acetylcholinesterase inhibitor, increases choline acetyltransferase activity in cultured rat septal cholinergic neurons. Neurosci Lett 260 (1999) 5-8
17. Kemppainen N., Laine M., Laakso M.P., Kaasinen V., Nagren K., Vahlberg T., et al. Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease. Eur J Neurosci 18 1 (2003) 149-154
18. Kiray M., Bagriyanik H.A., Pekcetin C., Ergur B.U., Uysal N., Ozyurt D., et al. Deprenyl and the relationship between its effects on spatial memory, oxidant stress and hippocampal neurons in aged male rats. Physiol Res 55 2 (2006) 205-212
19. Lisman J.E., and Otmakhova N.A. Storage, recall, and novelty detection of sequences by the hippocampus: elaborating on the SOCRATIC model to account for normal and aberrant effects of dopamine. Hippocampus 11 5 (2001) 551-568
20. Maurice T., Lockhart B.P., and Privat A. Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. Brain Res 706 2 (1996) 181-193
21. 1 receptor. Br J Pharmacol 149 (2006) 998-1012
22. Mouri A., Noda Y., Hara H., Mizoguchi H., Tabira T., and Nabeshima T. Oral vaccination with a viral vector containing Aβ cDNA attenuates age-related Aβ accumulation and memory deficits without causing inflammation in a mouse Alzheimer model. FASEB J 21 (2007) 2135-2148
23. Olariu A., Tran M.H., Yamada K., Mizuno M., Hefco V., and Nabeshima T. Memory deficits and increased emotionality induced by beta-amyloid (25-35) are correlated with the reduced acetylcholine release and altered phorbol dibutyrate binding in the hippocampus. J Neural Transm 108 8-9 (2001) 1065-1079
24. Otmakhova N.A., and Lisman J.E. D1/D5 dopamine receptor activation increases the magnitude of early long-term potentiation at CA1 hippocampal synapses. J Neurosci 16 23 (1996) 7478-7486
25. Perez-Severiano F., Salvatierra-Sanchez R., Rodriguez-Perez M., Cuevas-Martinez E.Y., Guevara J., Limon D., et al. S-Allylcysteine prevents amyloid-beta peptide-induced oxidative stress in rat hippocampus and ameliorates learning deficits. Eur J Pharmacol 489 3 (2004) 197-202
26. Perry E.K., Tomlinson B.E., Blessed G., Bergmann K., Gibson P.H., and Perry R.H. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 2 6150 (1978) 1457-1459
27. Remy P., and Samson Y. The role of dopamine in cognition: evidence from functional imaging studies. Curr Opin Neurol 16 Suppl. 2 (2003) S37-S41
28. Salonen J.S., Nyman L., Boobis A.R., Edwards R.J., Watts P., Lake B.G., et al. Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. Drug Metab Dispos 31 9 (2003) 1093-1102
29. Shen Y.X., Xu S.Y., Wei W., Sun X.X., Liu L.H., Yang J., et al. The protective effects of melatonin from oxidative damage induced by amyloid beta-peptide 25-35 in middle-aged rats. J Pineal Res 32 2 (2002) 85-89
30. Shimazu S., Sekimoto H., Tanida N., Yamaoka E., and Ohde H. Effect of selegiline on cholinergic system of brain and learning behavior. Neurobiol Aging 17 (1996) S-29-S-30
31. Svensson A.L., and Nordberg A. Tacrine and donepezil attenuate the neurotoxic effect of A beta(25-35) in rat PC12 cells. Neuroreport 9 7 (1998) 1519-1522
32. Tabner B.J., Turnbull S., El-Agnaf O.M., and Allsop D. Formation of hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease. Free Radic Biol Med 32 11 (2002) 1076-1083
33. Takahata K., Minami A., Kusumoto H., Shimazu S., and Yoneda F. Effects of selegiline alone or with donepezil on memory impairment in rats. Eur J Pharmacol 518 2-3 (2005) 140-144
34. Takahata K., Shimazu S., Katsuki H., Yoneda F., and Akaike A. Effects of selegiline on antioxidant systems in the nigrostriatum in rat. J Neural Transm 113 2 (2006) 151-158
35. Tariot P.N., Cohen R.M., Sunderland T., Newhouse P.A., Yount D., Mellow A.M., et al. l-Deprenyl in Alzheimer's disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition. Arch Gen Psychiatry 44 5 (1987) 427-433
36. Tran M.H., Yamada K., Olariu A., Mizuno M., Ren X.H., and Nabeshima T. Amyloid beta-peptide induces nitric oxide production in rat hippocampus: association with cholinergic dysfunction and amelioration by inducible nitric oxide synthase inhibitors. FASEB J 15 8 (2001) 1407-1409
37. Trubetskaya V.V., Stepanichev M.Y., Onufriev M.V., Lazareva N.A., Markevich V.A., and Gulyaeva N.V. Administration of aggregated beta-amyloid peptide (25-35) induces changes in long-term potentiation in the hippocampus in vivo. Neurosci Behav Physiol 33 2 (2003) 95-98
38. Wang D., Noda Y., Zhou Y., Mouri A., Mizoguchi H., Nitta A., et al. The allosteric potentiation of nicotinic acetylcholine receptors by galantamine ameliorates the cognitive dysfunction in beta amyloid 25-35 i.c.v-injected mice: involvement of dopaminergic systems. Neuropsychopharmacology 32 6 (2007) 1261-1271
39. Whitehead S.N., Hachinski V.C., and Cechetto D.F. Interaction between a rat model of cerebral ischemia and beta-amyloid toxicity: inflammatory responses. Stroke 36 1 (2005) 107-112
40. Yamada K., Tanaka T., Han D., Senzaki K., Kameyama T., and Nabeshima T. Protective effects of idebenone and alpha-tocopherol on beta-amyloid-(1-42)-induced learning and memory deficits in rats: implication of oxidative stress in beta-amyloid-induced neurotoxicity in vivo. Eur J Neurosci 11 1 (1999) 83-90
41. Yamamuro Y., Hori K., Tanaka J., Iwano H., and Nomura M. Septo-hippocampal cholinergic system under the discrimination learning task in the rat: a microdialysis study with the dual-probe approach. Brain Res 684 1 (1995) 1-7
42. Yang S.N. Sustained enhancement of AMPA receptor- and NMDA receptor-mediated currents induced by dopamine D1/D5 receptor activation in the hippocampus: an essential role of postsynaptic Ca2+. Hippocampus 10 1 (2000) 57-63
43. Yankner B.A., Duffy L.K., and Kirschner D.A. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 250 4978 (1990) 279-282